Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2010
12/29/2010CN101932939A Marker for determination of sensitivity to anti-cancer agent
12/29/2010CN101932338A Method for determination of sensitivity to anti-cancer agent
12/29/2010CN101932321A Combination therapy comprising sglt inhibitors and dpp4 inhibitors
12/29/2010CN101932320A Membrane fusion inhibitor
12/29/2010CN101928706A Technology for regulating up expression of ARE elements in DRD1 (Dopamine Receptor D1) mRNA 3-end non-coding region by stabilizing DRD1 mRNA
12/29/2010CN101928692A Differentiated cells suitable for human therapy
12/29/2010CN101928288A Small molecule compositions for binding to HSP90
12/29/2010CN101926999A Hemostatic disinfectant and preparation method thereof
12/29/2010CN101926998A Expression of embryo type globin induced by adrenoreceptor agonist and application thereof
12/29/2010CN101926997A Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity
12/29/2010CN101926996A Application of methotrexate and ABC inhibitor to preparation of medicament for treating psoriasis
12/29/2010CN101926783A Drug slow control releaser and preparation method thereof
12/29/2010CN101926773A Medicament-carrying lipoid particulates and preparation method thereof
12/29/2010CN101926770A Drug-loaded liposome and preparation method thereof
12/29/2010CN101417132B Use of medicine combination comprising carvedilol and angiotensin II recipient antagonist in preparing medicine for treating kidney disease
12/29/2010CN101380320B The use of cholinesterase inhibitors in pharmacy
12/29/2010CA2766197A1 Pharmaceutical composition for emergency contraception
12/29/2010CA2764423A1 Preparation comprising insulin, nicotinamide and an amino acid
12/29/2010CA2763299A1 Method for treating or ameliorating mucocutaneous or ocular toxicities
12/28/2010USRE42012 Compositions and methods for enhancing receptor-mediated cellular internalization
12/28/2010US7858662 Medicament for the treatment of viral skin and tumour diseases
12/28/2010US7858659 Redox therapy for tumors
12/28/2010US7858655 synergistic mixtures reduce damage to neurons after a neurodegenerative insult; time-release agents; antiischemic agents; amyotrophic lateral slerosis (ALS), Alzheimer's disease, Parkinson's disease, Hunntington's disease, multiple sclerosis
12/28/2010US7858605 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
12/28/2010US7858597 formulations of ANGIOTENSIN II AT1 receptors antagonists, using the cyclodextrins or their derivatives, lipossomes and the biodegradable polymers; increasing the bio-availability of losartan
12/28/2010US7858589 A saponin possessing immune adjuvant activity, derived from Quillaja saponaria; an immunostimulatory oligonucleotide cotaining an unmethylated CpG dinucleotide,wherein the immunostimulatory oligonucleotide is not a part of a DNA vaccine vector
12/28/2010US7858588 Oligodeoxynucleic acid modified with (thio)phosphate
12/28/2010US7858577 Use of the long pentraxin PTX3 for the treatment of diseases caused by an altered activation of the growth factor FGF-2
12/28/2010US7858312 Method of treating bladder and lower urinary tract syndromes
12/28/2010US7858103 Characterizing inflammatory mediator for use in generating antibodies for prevention and treatment of helicobacter infection; immunotherapy
12/28/2010US7858094 Controling abberant inflamatory response; obtain animal, incubate with modulator of inflammation, monitor animal for adjustment in inflammatory response
12/28/2010US7858085 Reducing blood glucose level in a non-obese or obese human afflicted with Type 2 diabetes by administering purified human placental alkaline phosphatase
12/28/2010US7858081 Peptide which is part of epitope in human IL-15 responsible for high-affinity binding of IL-15 to IL-15Ralpha chain, characterized in that it has sequence of region of human mature wild-type IL-15 from L44 to L52, or sequence of region of human mature wild-type IL-15 from E64 to I68 or from E64 to L69
12/23/2010WO2010147831A1 Dendrimer based nanodevices for therapeutic and imaging purposes
12/23/2010WO2010147238A1 Agent for preventing or treating abnormality in skin water permeation function
12/23/2010WO2010147145A1 Anti-gram-negative bacteria agent
12/23/2010WO2010146634A1 Immunotherapeutic agent and immunotherapy for pancreatic cancer
12/23/2010WO2010146478A1 Parenteral composition comprising a fluoroquinolone compound and a nitroimidazole compound
12/23/2010WO2010146055A1 Antagonists of beta-catenin for preventing and/or treating neurodegenerative disorders
12/23/2010WO2010145035A1 Renal cell carcinoma biomarkers
12/23/2010WO2010095158A8 Pharmaceutical composition containing microcolloidal silver and carboxymethyl beta glucan for disinfection of the nasal mucosae, and process for preparation thereof
12/23/2010WO2010080757A3 Combinations with an alpha-4beta-2 nicotinic agonist
12/23/2010US20100325743 Marks as modifiers of the p53 pathway and methods of use
12/23/2010US20100323987 Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
12/23/2010US20100323981 Treatment of statin side effects
12/23/2010US20100323952 Nucleoside Analogs in Combination Therapy of Herpes Simplex Infections
12/23/2010US20100323008 Solid dosage form comprising a fibrate
12/23/2010US20100322902 Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle
12/23/2010US20100322899 Methods of improving central nervous system functioning
12/23/2010US20100322853 Nanoparticulate compositions of angiogenesis inhibitors
12/23/2010US20100322852 Nanoparticulate compositions of angiogenesis inhibitors
12/23/2010CA2765870A1 Renal cell carcinoma biomarkers
12/23/2010CA2765657A1 Anti-gram-negative bacteria agent
12/23/2010CA2765408A1 New crystalline form of pemirolast
12/22/2010EP2264172A1 Oligomeric compounds for the modulation of HIF-1alpha expression
12/22/2010EP2264072A1 Enhancement of antibody-mediated cytotoxicity.
12/22/2010EP2264064A1 Modified exendins and exendin agonists
12/22/2010EP2264047A1 High purity lipopeptides, lipopeptide micelles and processes for preparing same
12/22/2010EP2264032A2 Hiv protease inhibiting sulfonamides
12/22/2010EP2264028A1 Pyrazole compounds useful as protein kinase inhibitors
12/22/2010EP2263697A2 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
12/22/2010EP2263695A2 Method and preparation for treating depressions
12/22/2010EP2263694A1 Antitumor agent comprising the histone deacetylase inhibitor FK228 and a topoisomerase II inhibitor
12/22/2010EP2263680A1 Compressed pharmaceutical compositions comprising PEG and electrolytes
12/22/2010EP2263670A1 Use of angiotensin II receptor antagonists in order to increase insulin sensitivity
12/22/2010EP2263652A1 Aerosols comprising nanoparticle drugs
12/22/2010EP2263651A2 Low viscosity liquid dosage forms
12/22/2010EP2263650A2 Nanoparticulate megestrol formulations
12/22/2010EP2263649A1 Pharmacological adjuvants based on coordination compounds of d-metals
12/22/2010EP2263648A1 Ophthalmic composition
12/22/2010EP2263596A1 Dispensing apparatus and cartridge
12/22/2010EP2263465A1 Polyvalent conjugate vaccine for cancer
12/22/2010EP2262541A1 C2orf18 as target gene for cancer therapy and diagnosis
12/22/2010EP2262535A1 Use of a composition containing healing earth as an antacid
12/22/2010EP2262534A1 Palatable solid composition comprising antacid and saliva stimulant
12/22/2010EP2262525A1 Apoaequorin-containing compositions and methods of using same
12/22/2010EP2262502A1 Compositions and methods for alleviating depression or improving cognition
12/22/2010EP2262492A2 Methods of treating hyperacidic disorders
12/22/2010EP2262491A1 Therapy for disorders of the proximal digestive tract
12/22/2010EP2262476A1 Drug delivery to the anterior and posterior segments of the eye using eye drops.
12/22/2010EP1412317B1 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities
12/22/2010EP1390037B1 Use of glucocorticoid receptor-specific antagonists for the treatment of delirium
12/22/2010EP1364660B1 Drug-releasing system of biodegradable polymer type
12/22/2010EP1290182B1 Sphingosine kinase and uses thereof
12/22/2010EP1214064B1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores
12/22/2010EP1135496B1 Ucp5
12/22/2010CN1990045B Highly effective plaster for burn and scald and its preparation process
12/22/2010CN1812973B Indazole compounds useful as protein kinase inhibitors
12/22/2010CN1713926B Peritoneal dialysis method
12/22/2010CN1547477B Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
12/22/2010CN1481390B Immunomodulatory peptides derived from heat shock proteins and uses thereof
12/22/2010CN101925364A 14-3-3 antagonists for prevention and treatment of arthritis
12/22/2010CN101925354A Anti-inflammatory compositions and combinations
12/22/2010CN101921732A A virus causing respiratory tract illness in susceptible mammals
12/22/2010CN101921347A Hyaluronic acid derivative and drug containing the same
12/22/2010CN101921220A Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
12/22/2010CN101920016A Implants for administering substances and methods of producing implants
12/22/2010CN101920006A Cyclin Y and use thereof
12/22/2010CN101919971A Agent for locally preventing and treating body surface diseases
12/22/2010CN101919891A Scheme II safe anesthetic